title: The efficiency of fractionated parenteral iron treatment in CAPD patients.
abstract: Some chronic renal failure patients respond poorly to recombinant human erythropoietin (rHuEPO). In continuous ambulatory peritoneal dialysis (CAPD) patients, such a poor response may indicate inadequate dialysis or low body iron stores. To correct iron deficiency, once-a-week intravenous iron supplementation is recommended. However, hemodialysis patients receive iron supplements three times a week. This study was designed to compare the efficacy of iron supplementation between once-weekly and twice-weekly regimens. In both groups, rHuEPO doses were similar. Seventeen CAPD patients were studied. All had hemoglobin levels less than 10 g/dL. Ten patients were given 100 mg intravenous iron once weekly, and 7 were given 50 mg intravenous iron twice weekly until a total iron dose of 600 mg was achieved (stage I). The patients were crossed over to receive another 600 mg iron (stage II). Hematocrit increased significantly in patients receiving twice-a-week iron supplementation (+3.8% and 6%) compared to those receiving once-a-week iron supplementation (+1.3% and 1.4%) during stages I and II. The ferritin levels were not different between the groups. In conclusion, rHuEPO is more effective when administered with intravenous iron.
authors.affiliation: Department of Internal Medicine, Medical School of Ege University, Izmir, Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Akcicek
authors.forename: M
authors.initials: M
authors.lastname: Ozkahya
authors.forename: M
authors.initials: M
authors.lastname: Cirit
authors.forename: E
authors.initials: E
authors.lastname: Ok
authors.forename: A
authors.initials: A
authors.lastname: Unsal
authors.forename: H
authors.initials: H
authors.lastname: Toz
authors.forename: A
authors.initials: A
authors.lastname: Celik
authors.forename: G
authors.initials: G
authors.lastname: Atabay
authors.forename: A
authors.initials: A
authors.lastname: Basci
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood; D005937:Glucaric Acid; D006400:Hematocrit; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009934:Organization and Administration; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins; D013395:Sucrose / Q000008:administration & dosage*; D014168:Transferrin / Q000032:analysis
chemical_list: D005290:Ferric Compounds; D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D013395:Sucrose; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid